The incidence of cancer, and the success rates in therapy, oblige us to examine every avenue of approach. Accordingly, it is suggested that certain turn-of-the century publications be re-examined. The distinguished embryologist John Beard, following up his elucidation of the trophoblastic origin of the mammalian placenta, made certain observations about the common origin, behaviour and chemistry of both the pregnancy trophoblast and the cancer cell, and of the mechanisms which control both in a healthy subject. These conclusions were published as The Trophoblast Theory of Cancer1-. Some aspects of this hypothesis, supported by recent research and observation, may now offer enough evidence for its re-introduction into contemporary orthodox thinking. Current pilot work holds out the prospect of inexpensive and methodologically simple cancer therapy with few and manageable side effects.
Trophoblast theory Beard argued that cancer cells, irrespective of appearance, were characteristically trophoblast in behaviour, having their origin either in pregnancy complications or the stimulation of pluripotent repair cells. Thus, the invasion of the uterine lining by the cytotrophoblast during the first 56 days of pregnancy models the tumour; placental and malignant cells sharing common immune suppressive mechanisms. Similarly, the control of trophoblastic infiltration by the maternal pancreas enzymes, and the check and decay ofthe cytotrophoblast to the syncitial form with the appearance of the foetal pancreas proteases, models the containment of malignancy in the healthy subject. Accordingly, Beard proposed the therapeutic administration of a protease/amylase mixture to destroy that 'irresponsible trophoblast', the -cancer cell. The resulting early efforts may be summarized as follows:
(1) Crude extracts were used as pure materials were unavailable. Limited activity and shelf-life combined with toxicity and underdosage to produce failures. (2) We should note that while amylase splits HCGH the hormone facilitates the excretion of the enzyme. Thus the cell survives by the manufacture of 'anti-tryptic factors', the host by the production of 'tryptic factors' to oppose them; antithesis is a two way street. Therapeutics Treatment aims to remove the protection of the trophoblast, exposing it to macrophage and enzyme activity. Simplest technique is Kelley's, using the step ladder method to arrive at the effective dose. Give 50 tablets of Pancrex V Forte (or 12 g of powder) as a single dose on an empty stomach, repeated for five days. The effect is cumulative, short term. If no response, increase the dose by ten tablets or 2.5 g of powder per day, every fifth day. The correct dose always produces a noticeable effect and the patient must be warned of this, as the severity of the symptoms can be alarming. The general clinical picture is of the sudden onset of an acute flu-like infection, with rise in temperature, perspiration, shivering, headache, pulse rate changes, weakness and prostration, gastrointestinal rush, and nausea. The cardinal signs of inflammation will appear at tumour sites, known and unknown. Following such a reaction nauseous patients have been known to vomit bile containing necrotic tumour debris from remote sites. The patient must not be allowed to sink into an hepatic coma, so suspension of proteolytic enzymes and the start of detoxification procedures are mandatory. Coffee enemas will bring rapid relief, administer every two hours, minimum, until the crisis is relieved. Niacin by mouth (50 mg), freshly expressed fruit juice and peppermint tea will assist in the elimination of accumulated toxins. The general trend is for the severity of the symptoms to decrease as treatment progresses and the total tumour mass declines.
Simplistic writers ascribe the above symptoms to the circulating products of tumour cell breakdown -'necrosis toxaemia'-but the body copes with the catabolic produce of millions of somatic cells every day. Amylase, by mouth or added to the coffee enemas, relieves most of the symptoms, implicating HCGH as the major but not the sole cause. When the symptoms have gone for 24 hours resume with same dose but beware of post-crisis euphoria. However, a word of warning is needed. Amygdalin should not be administered while using oral enzymes. -Tumour destruction with the latter tends to be self-limiting but combined with amygdalin there is a synergic effect which has resulted in excessive destruction of malignant tissues; to misquote Dupuytren, eclampsia can slay as surely as cancer. Amygdalin can be a useful aid in malignancy, it is a pity that due to incorrect preparation, disinformation, and ill designed therapeutic approaches it'is not more widely used, but this is a case where, for the present, it must not be.
Supportive measures increase the effectiveness of the therapy. Short term exclusion from the diet of meat, animal fats, dairy products and oils will conserve intrinsic enzymes. Give hydrolized protein for amino acids, several glasses of carrot juice for beta carotene (Niepier's method) an anti-malignant factor as is selenium. Potassium, zinc and magnesium orotates should be given; large doses of vitamin C and weekly basal cell carcinoma inoculations are effective in conjunction with the therapy. The diet should be high in potassium and low in sodium.
The oral route, though simple, is crude. Given superior quality enzymes then the retention enema, intramuscular, intravenous, intra-arterial and intratumoural doses become not only possible but desirable. Increasingly with them both, side effects and doses are reduced and with the last, amygdalin is not contraindicated. The cardinal features still apply: (1) No response usually means too small a dose; in a small number of cases with previous iatrogenic damage the immune response is defective. (2) Persistance is indicated despite alarming reactions. To give up for this reason is to snatch failure from the jaws of success. (3) A maintenance dose is required after tumour elimination. Disappearance of the malignant mass must not be equated with a cure.
Discussion
Despite current primitive methods the time has come for serious controlled trials by concerned, independent workers and any thoughts, comments and suggestions are invited by the author. Some points where help would be advantageous follow: (1) The trophoblast theory is of aid to the clinician but is its acceptance fundamental? Could we proceed on the basis of the observation that certain enzymes have a specific action on malignant cells? (Kelly succeeded with a crude model; a surgeon can eliminate mammary carcinoma with intratumoural enzymes but no theory.) (2) There are indications that enzyme action is lowered in the cancer host because of: (a) reduced pancreas activity, (b) gut wall transmission impairment, (c) average bloodstream pH shift from optimum to alkaline and (d) subnormal specific hepatic functions. What is the quantitative balance between these factors? (3) Why is it often more difficult to elicit a favourable response from patients with a previous history oftreatment with cytotoxics? (4) It is reported privately that trophoblast and epithelial cells hybridize in utero. A specific journal reference is required.
